Abstract
Melanoma shows a high possibility of mortality after it metastasizes because of its aggressive nature. Although there are several options for anti-melanoma therapy, this skin malignancy is resistant to some therapies. Chemotherapy, biochemotherapy, immunotherapy, and adoptive cell therapy have failed to exhibit a significant amelioration in overall survival. Nanomedicine provides an opportunity to improve the efficiency of the antimelanoma regimen. Nanoparticles for treating melanoma provide the advantages over conventional therapies such as drug solubility increment, drug stability enhancement, epithelium permeability and bioavailability amelioration, half-life prolonging, tumor targeting, and side effect minimization. Polymeric nanocarriers are the most extensively studied platforms for the treatment of a variety of cancers. The polymers' sophisticated material engineering tailors the controllable physicochemical properties of the nanoparticles for melanoma penetration via passive and active delivery. The present study highlights the recent progress on the development of polymeric nanoparticles for melanoma treatment. We describe the concepts and improvement mechanisms of the nanomedical techniques for melanoma treatment. Passive targeting by modifying the structure and physicochemical characters of polymeric nanocarriers is a strategy for efficient drug delivery to the melanoma and its metastasis. On the other hand, active targeting such as peptide or antibody conjugation is another approach delivering the drugs or genes to the nidus site by the nanocarriers. This review offers an overview of the benefits of polymeric nanosystems for treating melanoma.
Keywords: Nanomedicine, polymeric nanoparticle, melanoma, metastasis, drug targeting, chemotherapy.
Current Pharmaceutical Design
Title:Recent Advances in Polymeric Nanosystems for Treating Cutaneous Melanoma and Its Metastasis
Volume: 23 Issue: 35
Author(s): Yi-Ping Chou, Yin-Ku Lin, Chun-Han Chen and Jia-You Fang*
Affiliation:
- Research Center for Industry of Human Ecology and Research Center for Chinese Herbal Medicine, Chang Gung University of Science and Technology, Kweishan, Taoyuan,Taiwan
Keywords: Nanomedicine, polymeric nanoparticle, melanoma, metastasis, drug targeting, chemotherapy.
Abstract: Melanoma shows a high possibility of mortality after it metastasizes because of its aggressive nature. Although there are several options for anti-melanoma therapy, this skin malignancy is resistant to some therapies. Chemotherapy, biochemotherapy, immunotherapy, and adoptive cell therapy have failed to exhibit a significant amelioration in overall survival. Nanomedicine provides an opportunity to improve the efficiency of the antimelanoma regimen. Nanoparticles for treating melanoma provide the advantages over conventional therapies such as drug solubility increment, drug stability enhancement, epithelium permeability and bioavailability amelioration, half-life prolonging, tumor targeting, and side effect minimization. Polymeric nanocarriers are the most extensively studied platforms for the treatment of a variety of cancers. The polymers' sophisticated material engineering tailors the controllable physicochemical properties of the nanoparticles for melanoma penetration via passive and active delivery. The present study highlights the recent progress on the development of polymeric nanoparticles for melanoma treatment. We describe the concepts and improvement mechanisms of the nanomedical techniques for melanoma treatment. Passive targeting by modifying the structure and physicochemical characters of polymeric nanocarriers is a strategy for efficient drug delivery to the melanoma and its metastasis. On the other hand, active targeting such as peptide or antibody conjugation is another approach delivering the drugs or genes to the nidus site by the nanocarriers. This review offers an overview of the benefits of polymeric nanosystems for treating melanoma.
Export Options
About this article
Cite this article as:
Chou Yi-Ping , Lin Yin-Ku , Chen Chun-Han and Fang Jia-You *, Recent Advances in Polymeric Nanosystems for Treating Cutaneous Melanoma and Its Metastasis, Current Pharmaceutical Design 2017; 23 (35) . https://dx.doi.org/10.2174/1381612823666170710121348
DOI https://dx.doi.org/10.2174/1381612823666170710121348 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Discovery of Inhibitors of Protein-Protein Interactions from Combinatorial Libraries
Current Topics in Medicinal Chemistry Immunotherapy and Cancer Vaccines in the Management of Breast Cancer
Current Pharmaceutical Design Synthesis and Stereochemistry-Activity Relationship of Chiral Thiourea Derivatives as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Clinical Trials Targeting Advanced Cancers by Active Immunization of T-cell Defined Tumor Antigens
Current Pharmaceutical Design Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer
Current Cancer Drug Targets Versatile Synthesis of Organic Compounds Derived from Ascorbic Acid
Current Organocatalysis Antiviral Drugs in the Prophylaxis of HBV Infection
Current Medicinal Chemistry Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry Vitamin-D in the Immune System: Genomic and Non-Genomic Actions
Mini-Reviews in Medicinal Chemistry Psychosocial Risk Factors Related to Ischemic Heart Disease in Women
Current Pharmaceutical Design Human Chorionic Gonadotropin: A Model Molecule For Oligopeptide-Based Drug Discovery
Endocrine, Metabolic & Immune Disorders - Drug Targets Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Recent Patents on Anti-Cancer Drug Discovery Vitiligo: Pathogenetic Hypotheses and Targets for Current Therapies
Current Drug Metabolism 2-(ω-Carboxyethyl)pyrrole Antibody as a New Inhibitor of Tumor Angiogenesis and Growth
Anti-Cancer Agents in Medicinal Chemistry Molecular Classification and Drug Response Prediction in Cancer
Current Drug Targets AP5346 (ProLindac™), A DACH Platinum Polymer Conjugate in Phase II Trials Against Ovarian Cancer
Current Bioactive Compounds Electronic Noses in Medical Diagnostics
Current Medicinal Chemistry Bowman-Birk Inhibitors from Legumes and Human Gastrointestinal Health: Current Status and Perspectives
Current Protein & Peptide Science Photochemical Reactions: Synthesis of Six-membered N-heterocycles
Current Organic Synthesis Vitamin D Supplementation and Cancer: Review of Randomized Controlled Trials
Anti-Cancer Agents in Medicinal Chemistry